Market Cap 112.57M
Revenue (ttm) 5.72M
Net Income (ttm) -75.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,318.36%
Debt to Equity Ratio 0.00
Volume 267,800
Avg Vol 2,762,512
Day's Range N/A - N/A
Shares Out 47.90M
Stochastic %K 61%
Beta 1.89
Analysts Sell
Price Target $2.31

Company Profile

Shattuck Labs, Inc., a biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases. The company's lead product candidate includes SL-325, a DR3 blocking monoclonal antibody, which activates immune responses through binding a single receptor, DR3; and SL-425. It also develops multiple preclinical DR3-based bispecific antibodies for the treatment of inflammatory bowel disease; and a series of bispecific antibodies targeting DR3 and other clinically val...

Industry: Biotechnology
Sector: Healthcare
Phone: 512 900 4690
Address:
500 West 5th Street, Suite 1200, Austin, United States
Caresto
Caresto Oct. 3 at 12:01 AM
$STTK good job, @YFZ450, Congrats! Way to drive!
0 · Reply
YFZ450
YFZ450 Oct. 2 at 8:14 PM
$STTK been stuck here a while finally out! low vol likely dumps, gl holders!
0 · Reply
grizzly3
grizzly3 Oct. 2 at 4:09 PM
$STTK Pipeline & Clinical Phases SL‑325 - Preclinical → transitioning to clinical (Phase 1) DR3‑based bispecifics / next‑generation candidates - Preclinical / nomination stage SL‑172154 (discontinued / deprioritized) - Previously clinical Many therapeutics fail due to toxicity, immunogenicity, or lack of efficacy in humans despite promising preclinical data. Although the recent capital raise is sizable, unfavorable outcomes or delays may still force future raises and dilution. As a small‑cap biotech, STTK’s valuation may be more volatile and sentiment-sensitive. Negative news, delays, or broader biotech sector pullbacks could disproportionately affect it Dependency on SL‑325 success: Given the pivot, the company is highly dependent on the success of this single program. Failure or underperformance could be damaging
0 · Reply
peepthestamp
peepthestamp Oct. 2 at 3:40 PM
1 · Reply
PepCF
PepCF Sep. 26 at 5:23 PM
0 · Reply
StockArbitrage
StockArbitrage Sep. 26 at 2:10 AM
$STTK Recruiting https://helpresearch.com/medical-study/ca45440-2a-0x00000000000067d2
0 · Reply
Stochalicious
Stochalicious Sep. 23 at 6:42 PM
0 · Reply
Pratik2024
Pratik2024 Sep. 21 at 12:09 PM
$ADAP $IXHL $LOBO $MWYN $STTK MWYN for coming days
0 · Reply
Kelsi1004
Kelsi1004 Sep. 19 at 3:08 PM
$ADAP $IXHL $LOBO $MWYN $STTK Is MWYN again?
0 · Reply
FetchDog
FetchDog Sep. 18 at 9:22 PM
$STTK The stock has been pumped up so institutional investors can dump on the heads of retail investors (i.e. future bag holders). From the S-3, these investors will be selling 100% of their shares (including shares obtained after exercise of warrants): Orbimed Advisors (36,879,576 shares), Baker Bros.(17,415,356 shares), Coastlands Capital Partners (11,524,868 shares), Entities Affiliated with NEXTBio (7,683,244 shares). Other investors will be selling a large percentage of their shares (including shares obtained after exercise of warrants): Redmile Group (selling 8,195,460 of 16,948,943 shares), Prosight Management (selling 9,732,110 of 16,510,563 shares), Adage Capital Partners (selling 8,707,678 of 13,382,678 shares), etc. Exercise of warrants will increase share count by around 188% while bringing in little cash ($57 million).
0 · Reply
Latest News on STTK
Caresto
Caresto Oct. 3 at 12:01 AM
$STTK good job, @YFZ450, Congrats! Way to drive!
0 · Reply
YFZ450
YFZ450 Oct. 2 at 8:14 PM
$STTK been stuck here a while finally out! low vol likely dumps, gl holders!
0 · Reply
grizzly3
grizzly3 Oct. 2 at 4:09 PM
$STTK Pipeline & Clinical Phases SL‑325 - Preclinical → transitioning to clinical (Phase 1) DR3‑based bispecifics / next‑generation candidates - Preclinical / nomination stage SL‑172154 (discontinued / deprioritized) - Previously clinical Many therapeutics fail due to toxicity, immunogenicity, or lack of efficacy in humans despite promising preclinical data. Although the recent capital raise is sizable, unfavorable outcomes or delays may still force future raises and dilution. As a small‑cap biotech, STTK’s valuation may be more volatile and sentiment-sensitive. Negative news, delays, or broader biotech sector pullbacks could disproportionately affect it Dependency on SL‑325 success: Given the pivot, the company is highly dependent on the success of this single program. Failure or underperformance could be damaging
0 · Reply
peepthestamp
peepthestamp Oct. 2 at 3:40 PM
1 · Reply
PepCF
PepCF Sep. 26 at 5:23 PM
0 · Reply
StockArbitrage
StockArbitrage Sep. 26 at 2:10 AM
$STTK Recruiting https://helpresearch.com/medical-study/ca45440-2a-0x00000000000067d2
0 · Reply
Stochalicious
Stochalicious Sep. 23 at 6:42 PM
0 · Reply
Pratik2024
Pratik2024 Sep. 21 at 12:09 PM
$ADAP $IXHL $LOBO $MWYN $STTK MWYN for coming days
0 · Reply
Kelsi1004
Kelsi1004 Sep. 19 at 3:08 PM
$ADAP $IXHL $LOBO $MWYN $STTK Is MWYN again?
0 · Reply
FetchDog
FetchDog Sep. 18 at 9:22 PM
$STTK The stock has been pumped up so institutional investors can dump on the heads of retail investors (i.e. future bag holders). From the S-3, these investors will be selling 100% of their shares (including shares obtained after exercise of warrants): Orbimed Advisors (36,879,576 shares), Baker Bros.(17,415,356 shares), Coastlands Capital Partners (11,524,868 shares), Entities Affiliated with NEXTBio (7,683,244 shares). Other investors will be selling a large percentage of their shares (including shares obtained after exercise of warrants): Redmile Group (selling 8,195,460 of 16,948,943 shares), Prosight Management (selling 9,732,110 of 16,510,563 shares), Adage Capital Partners (selling 8,707,678 of 13,382,678 shares), etc. Exercise of warrants will increase share count by around 188% while bringing in little cash ($57 million).
0 · Reply
FetchDog
FetchDog Sep. 18 at 8:19 PM
$STTK S-3 posted to sell 105,270,692 shares of common stock by selling shareholders. Shares to be sold: (i) 15,225,158 shares of Common Stock, (ii) 37,410,188 shares of Common Stock issuable upon the exercise of pre-funded warrants with a per share exercise price equal to $0.0001 and (iii) 52,635,346 shares of Common Stock issuable upon (x) the exercise of common warrants with a per share exercise price of $1.0846
0 · Reply
DARKP00L
DARKP00L Sep. 18 at 6:56 PM
$STTK the market is buzzing about this stock. Expect possible price changes!
0 · Reply
prismmarketview
prismmarketview Sep. 18 at 3:58 PM
PRISM MarketView Mid-Day Movers: $WBTN (WEBTOON Entertainment) surged 39.04%, leading gains in Comms & Media! $ABTS (Crypto Mining) also climbed strong. Market shows renewed confidence in growth sectors. Other Notable Movers: $STTK: (Shattuck Labs, Inc.) Up 19.553% $NUMIF: (Numinus Wellness Inc.) Up 23.188% $TFFP: (TFF Pharmaceuticals, Inc.) Down -60.049%. https://prismmarketview.com/prism-marketview-mid-day-movers-webtoon-rockets-crypto-mining-and-biotech-stocks-also-climb/
0 · Reply
GMExAPE
GMExAPE Sep. 17 at 9:13 PM
RMFC stock has 5X potential, shorts at zero borrow and the 3m float is locked. Very undervalued here - No dilution - Catalysts coming - Just reported record financials and added a new store a few weeks ago. WATCHING - $LVO $QCVGA $DSY $VNTG $STTK
1 · Reply
SoaringEagles
SoaringEagles Sep. 17 at 1:50 AM
$EDUC Going to be a fun day here tomorrow! So many runners and I think this is next to go big! $STTK $LOCL $MFH $ATCH
0 · Reply
MegaSift
MegaSift Sep. 17 at 1:09 AM
$STTK insider buying, upward momentum. Who’s got the news to break this one wide open?
0 · Reply
ChazzyTrades
ChazzyTrades Sep. 16 at 8:35 PM
$STTK one to watch
0 · Reply
StockmamaG
StockmamaG Sep. 16 at 8:15 PM
$STTK Is anyone else watching this?😳
1 · Reply
Thess5
Thess5 Sep. 14 at 5:46 PM
$OPI Hit this at .56 Friday. Loaded! Looking for .80+ Monday! Other winners; $NEON $4.10. Out at $6.95 $STTK. $1.23. Out at $1.51 $GCTK $8.92. Out at $10.89
0 · Reply
PepCF
PepCF Sep. 12 at 5:51 AM
0 · Reply
Bretomo
Bretomo Sep. 11 at 3:22 PM
$STTK I love this stock
0 · Reply
algo888
algo888 Sep. 10 at 2:18 PM
$STTK move profits to (EQ) up 7%
0 · Reply